Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.

Authors :: Bruzzese A
Assanto GM
Diverio D
Quattrocchi L
Carmini D
La Rocca U
De Propris MS
Trisolini SM
Brescini M
Galassi G
Barberi W
Iori AP
Source :: Bone marrow transplantation [Bone Marrow Transplant] 2021 Jun; Vol. 56 (6), pp. 1455-1457. Date of Electronic Publication: 2021 Jan 29.
Publication Year :: 2021

Subjects :: Humans
Mutation
Sorafenib therapeutic use
fms-Like Tyrosine Kinase 3 genetics
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Leukemia, Myeloid, Acute therapy

Full Text Access

Tools